Biopsies from the same patients before and after treatment reveal how a specific drug reprograms prostate tumors.

Findings suggest this method could provide data about tumors sooner than MRIs alone.

Researchers discover how a gene mutation in the cancerous tumor leads to cell cycle dysregulation and heightened sensitivity to a class of inhibitors.

The anti-cancer effect of the drug may help those with rare, hereditary cancer syndromes avoid surgeries by shrinking tumors via a daily oral dose.

An open access, online repository accelerates advancements in cancer prevention and prediction.

Newer genetic tests introduce more ambiguity, but a new study finds patients are not overreacting to uncertain results.